ProKidney (NASDAQ: PROK) insider transactions
In the twelve months to 10 November 2026, executives and directors of ProKidney reported 10 open-market sales of 1,514,326 shares ($3.0m) and 0 open-market purchases, by 1 person, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 28 October 2026 | Weber Darin J. | Chief Regulatory Officer | Conversion | +200,000 | — | 200,000 | Form 4 |
| 20 August 2026 | Pereira Brian JG | Director | Open-market sale | −222,948 | $1.42 | 0 | Form 4 |
| 20 August 2026 | Pereira Brian JG | Director | Open-market sale | −27,052 | $1.42 | 0 | Form 4 |
| 19 August 2026 | Pereira Brian JG | Director | Open-market sale | −222,949 | $1.44 | 222,948 | Form 4 |
| 19 August 2026 | Pereira Brian JG | Director | Open-market sale | −27,051 | $1.44 | 27,052 | Form 4 |
| 18 August 2026 | Pereira Brian JG | Director | Open-market sale | −229,338 | $1.37 | 445,897 | Form 4 |
| 18 August 2026 | Pereira Brian JG | Director | Open-market sale | −27,826 | $1.37 | 54,103 | Form 4 |
| 4 August 2026 | Pereira Brian JG | Director | Conversion | +81,929 | — | 81,929 | Form 4 |
| 4 August 2026 | Pereira Brian JG | Director | Conversion | +675,235 | — | 675,235 | Form 4 |
| 12 June 2026 | Girolamo Todd C | Chief Legal Officer | Conversion | +163,857 | — | 327,713 | Form 4 |
| 28 April 2026 | Control Empresarial de Capitales S.A. de C.V. | — | Conversion | +63,118,645 | — | 73,842,723 | Form 4 |
| 13 November 2025 | Pereira Brian JG | Director | Open-market sale | −447,803 | $2.37 | 0 | Form 4 |
| 13 November 2025 | Pereira Brian JG | Director | Open-market sale | −54,333 | $2.37 | 0 | Form 4 |
| 12 November 2025 | Pereira Brian JG | Director | Open-market sale | −227,431 | $2.72 | 447,803 | Form 4 |
| 12 November 2025 | Pereira Brian JG | Director | Open-market sale | −27,595 | $2.72 | 54,333 | Form 4 |
| 8 July 2025 | Weber Darin J. | Chief Regulatory Officer | Open-market sale | −103,480 | $3.02 | 0 | Form 4 |
| 3 June 2025 | Legorreta Pablo G. | Director | Conversion | +3,823,996 | — | 26,441,905 | Form 4 |
| 3 June 2025 | Legorreta Pablo G. | Director | Other | −3,823,996 | — | 22,617,909 | Form 4 |
| 22 April 2025 | Control Empresarial de Capitales S.A. de C.V. | — | Open-market purchase | +387,393 | $0.71 | 73,842,723 | Form 4 |
| 17 April 2025 | Control Empresarial de Capitales S.A. de C.V. | — | Open-market purchase | +25,000 | $0.75 | 73,455,330 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the ProKidney page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.